Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, Staples JE, Tomori O, Wilder-Smith A, Monath TP; Informal WHO Working Group on Geographic Risk for Yellow Fever, 2011. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis 11: 622–632.

JentesESPoumerolGGershmanMDHillDRLemarchandJLewisRFStaplesJETomoriOWilder-SmithAMonathTP; Informal WHO Working Group on Geographic Risk for Yellow Fever, 2011. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis 11: 622–632.)| false
• Search Google Scholar
• Export Citation

Wilson ME, Chen LH, Barnett ED, 2004. Yellow fever immunizations: indications and risks. Curr Infect Dis Rep 6: 34–42.

WilsonMEChenLHBarnettED, 2004. Yellow fever immunizations: indications and risks. Curr Infect Dis Rep 6: 34–42.)| false
• Search Google Scholar
• Export Citation

Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE, 2007. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine 25: 2758–2765.

BarrettADMonathTPBarbanVNiedrigMTeuwenDE, 2007. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine 25: 2758–2765.)| false
• Search Google Scholar
• Export Citation

Staples JE, Gershman M, Fischer M; Centers for Disease Control and Prevention, 2010. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 59: 1–27.

StaplesJEGershmanMFischerM; Centers for Disease Control and Prevention, 2010. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 59: 1–27.)| false
• Search Google Scholar
• Export Citation

Wilder-Smith A, Hill DR, Freedman DO, 2008. The revised International Health Regulations (2005): impact on yellow fever vaccination in clinical practice. Am J Trop Med Hyg 78: 359–360.

Wilder-SmithAHillDRFreedmanDO, 2008. The revised International Health Regulations (2005): impact on yellow fever vaccination in clinical practice. Am J Trop Med Hyg 78: 359–360.)| false
• Search Google Scholar
• Export Citation

Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'Age-Stehr J, 1998. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56: 159–167.

ReinhardtBJaspertRNiedrigMKostnerCL'Age-StehrJ, 1998. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56: 159–167.)| false
• Search Google Scholar
• Export Citation

Gomez SY, Ocazionez RE, 2008. Yellow fever virus 17D neutralizing antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue [in Spanish]. Rev Salud Publica (Bogota) 10: 796–807.

GomezSYOcazionezRE, 2008. Yellow fever virus 17D neutralizing antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue [in Spanish]. Rev Salud Publica (Bogota) 10: 796–807.)| false
• Search Google Scholar
• Export Citation

Groot H, Riberiro RB, 1962. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 year(s) after vaccination with 17D vaccine. Bull World Health Organ 27: 699–707.

GrootHRiberiroRB, 1962. Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 year(s) after vaccination with 17D vaccine. Bull World Health Organ 27: 699–707.)| false
• Search Google Scholar
• Export Citation

Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K, 1981. Persistence of neutralizing antibody 30–35 year(s) after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895–900.

PolandJDCalisherCHMonathTPDownsWGMurphyK, 1981. Persistence of neutralizing antibody 30–35 year(s) after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895–900.)| false
• Search Google Scholar
• Export Citation

de Melo AB, da Silva M da P, Magalhaes MC, Gonzales Gil LH, Freese de Carvalho EM, Braga-Neto UM, Bertani GR, Marques ET Jr, Cordeiro MT, 2011. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 85: 739–747.

de MeloABda SilvaM da PMagalhaesMCGonzales GilLHFreese de CarvalhoEMBraga-NetoUMBertaniGRMarquesETJrCordeiroMT, 2011. Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. Am J Trop Med Hyg 85: 739–747.)| false
• Search Google Scholar
• Export Citation

Rosenzweig EC, Babione RW, Wisseman CL Jr, 1963. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg 12: 230–235.

RosenzweigECBabioneRWWissemanCLJr, 1963. Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg 12: 230–235.)| false
• Search Google Scholar
• Export Citation

Niedrig M, Lademann M, Emmerich P, Lafrenz M, 1999. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 4: 867–871.

NiedrigMLademannMEmmerichPLafrenzM, 1999. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 4: 867–871.)| false
• Search Google Scholar
• Export Citation

Coulange Bodilis H, Benabdelmoumen G, Gergely A, Goujon C, Pelicot M, Poujol P, Consigny PH, 2011. Long term persistence of yellow fever neutralizing antibodies in elderly persons [in French]. Bull Soc Pathol Exot 104: 260–265.

Coulange BodilisHBenabdelmoumenGGergelyAGoujonCPelicotMPoujolPConsignyPH, 2011. Long term persistence of yellow fever neutralizing antibodies in elderly persons [in French]. Bull Soc Pathol Exot 104: 260–265.)| false
• Search Google Scholar
• Export Citation

Centers for Disease Control and Prevention, 2010. Transmission of yellow fever vaccine virus through breast-feeding–Brazil, 2009. MMWR Morb Mortal Wkly Rep 59: 130–132.

Centers for Disease Control and Prevention, 2010. Transmission of yellow fever vaccine virus through breast-feeding–Brazil, 2009. MMWR Morb Mortal Wkly Rep 59: 130–132.)| false
• Search Google Scholar
• Export Citation

Kuhn S, Twele-Montecinos L, MacDonald J, Webster P, Law B, 2011. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 183: E243–E245.

KuhnSTwele-MontecinosLMacDonaldJWebsterPLawB, 2011. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 183: E243–E245.)| false
• Search Google Scholar
• Export Citation

Anonymous, 2011. Meeting of the Global Advisory Committee on Vaccine Safety, December 2010. Wkly Epidemiol Rec 86: 38–43.

Anonymous, 2011. Meeting of the Global Advisory Committee on Vaccine Safety, December 2010. Wkly Epidemiol Rec 86: 38–43.)| false
• Search Google Scholar
• Export Citation

Kengsakul K, Sathirapongsasuti K, Punyagupta S, 2002. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85: 131–134.

KengsakulKSathirapongsasutiKPunyaguptaS, 2002. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85: 131–134.)| false
• Search Google Scholar
• Export Citation

Mason RA, Tauraso NM, Ginn RK, O'Brien TC, Trimmer RW, 1972. Yellow fever vaccine. V. Antibody response in maonkeys inoculated with graded doses of the 17D vaccine. Appl Microbiol 23: 908–913.

MasonRATaurasoNMGinnRKO'BrienTCTrimmerRW, 1972. Yellow fever vaccine. V. Antibody response in maonkeys inoculated with graded doses of the 17D vaccine. Appl Microbiol 23: 908–913.)| false
• Search Google Scholar
• Export Citation

Mason RA, Tauraso NM, Spertzel RO, Ginn RK, 1973. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25: 539–544.

MasonRATaurasoNMSpertzelROGinnRK, 1973. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25: 539–544.)| false
• Search Google Scholar
• Export Citation

Staples JE, Gershman M, Fischer M; Centers for Disease Control and Prevention, 2010. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 59: 1–27.

StaplesJEGershmanMFischerM; Centers for Disease Control and Prevention, 2010. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 59: 1–27.)| false
• Search Google Scholar
• Export Citation

Julander JG, Trent DW, Monath TP, 2011. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine 29: 6008–6016.

JulanderJGTrentDWMonathTP, 2011. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine 29: 6008–6016.)| false
• Search Google Scholar
• Export Citation

Hombach J, Solomon T, Kurane I, Jacobson J, Wood D, 2005. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23: 5205–5211.

HombachJSolomonTKuraneIJacobsonJWoodD, 2005. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 23: 5205–5211.)| false
• Search Google Scholar
• Export Citation

Monath TP, 2005. Yellow fever vaccine. Expert Rev Vaccines 4: 553–574.

MonathTP, 2005. Yellow fever vaccine. Expert Rev Vaccines 4: 553–574.)| false
• Search Google Scholar
• Export Citation

Hepburn MJ, Kortepeter MG, Pittman PR, Boudreau EF, Mangiafico JA, Buck PA, Norris SL, Anderson EL, 2006. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 24: 2843–2849.

HepburnMJKortepeterMGPittmanPRBoudreauEFMangiaficoJABuckPANorrisSLAndersonEL, 2006. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 24: 2843–2849.)| false
• Search Google Scholar
• Export Citation

Groot H, Gast-Galvis A, 1965. Observations on the 17 D virus vaccine against yellow fever, applied by cutaneous scarification [in Spanish]. Rev Invest (Guadalajara) 5: 5–25.

GrootHGast-GalvisA, 1965. Observations on the 17 D virus vaccine against yellow fever, applied by cutaneous scarification [in Spanish]. Rev Invest (Guadalajara) 5: 5–25.)| false
• Search Google Scholar
• Export Citation

Guerra HL, Sardinha TM, da Rosa AP, Lima e Costa MF, 1997. Effectiveness of the yellow fever vaccine 17D: an epidemiologic evaluation in health services [in Spanish]. Rev Panam Salud Publica 2: 115–120.

GuerraHLSardinhaTMda RosaAPLima e CostaMF, 1997. Effectiveness of the yellow fever vaccine 17D: an epidemiologic evaluation in health services [in Spanish]. Rev Panam Salud Publica 2: 115–120.)| false
• Search Google Scholar
• Export Citation

Vazquez S, Valdes O, Pupo M, Delgado I, Alvarez M, Pelegrino JL, Guzmán MG, 2003. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. J Virol Methods 110: 179–184.

VazquezSValdesOPupoMDelgadoIAlvarezMPelegrinoJLGuzmánMG, 2003. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination. J Virol Methods 110: 179–184.)| false
• Search Google Scholar
• Export Citation

Camacho LA, Freire M da S, Leal M da L, Aguiar SG, Nascimento JP, Iguchi T, Lozana J de A, Farias RH; Collaborative Group for the Study of Yellow Fever Vaccines, 2004. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 38: 671–678.

CamachoLAFreireM da SLealM da LAguiarSGNascimentoJPIguchiTLozanaJ de AFariasRH; Collaborative Group for the Study of Yellow Fever Vaccines, 2004. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 38: 671–678.)| false
• Search Google Scholar
• Export Citation

Tavares-Neto J, Freitas-Carvalho J, Nunes MR, Rocha G, Rodrigues SG, Damasceno E, Darub R, Viana S, Vasconcelos PF, 2004. Serologic survey for yellow fever and other arboviruses among inhabitants of Rio Branco, Brazil, before and three months after receiving the yellow fever 17D vaccine [in Portuguese]. Rev Soc Bras Med Trop 37: 1–6.

Tavares-NetoJFreitas-CarvalhoJNunesMRRochaGRodriguesSGDamascenoEDarubRVianaSVasconcelosPF, 2004. Serologic survey for yellow fever and other arboviruses among inhabitants of Rio Branco, Brazil, before and three months after receiving the yellow fever 17D vaccine [in Portuguese]. Rev Soc Bras Med Trop 37: 1–6.)| false
• Search Google Scholar
• Export Citation

Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magill AJ, Pastor-Cauna G, Echevarria C, Laguna-Torres VA, Samame BK, Baldeon ME, Burnas JP, Olson JG, Bedford P, Kitchener S, Monath TP, 2005. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 72: 189–197.

Belmusto-WornVESanchezJLMcCarthyKNicholsRBautistaCTMagillAJPastor-CaunaGEchevarriaCLaguna-TorresVASamameBKBaldeonMEBurnasJPOlsonJGBedfordPKitchenerSMonathTP, 2005. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 72: 189–197.)| false
• Search Google Scholar
• Export Citation

Pfister M, Kursteiner O, Hilfiker H, Favre D, Durrer P, Ennaji A, L'Age-Stehr J, Kaufhold A, Herzog C, 2005. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg 72: 339–346.

PfisterMKursteinerOHilfikerHFavreDDurrerPEnnajiAL'Age-StehrJKaufholdAHerzogC, 2005. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg 72: 339–346.)| false
• Search Google Scholar
• Export Citation

Suzano CE, Amaral E, Sato HK, Papaiordanou PM; Campinas Group on Yellow Fever Immunization during Pregnancy, 2006. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24: 1421–1426.

SuzanoCEAmaralESatoHKPapaiordanouPM; Campinas Group on Yellow Fever Immunization during Pregnancy, 2006. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24: 1421–1426.)| false
• Search Google Scholar
• Export Citation

Monath TP, Nichols R, Archambault WT, Moore L, Marchesani R, Tian J, Shope RE, Thomas N, Schrader R, Furby D, Bedford P, 2002. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66: 533–541.

MonathTPNicholsRArchambaultWTMooreLMarchesaniRTianJShopeREThomasNSchraderRFurbyDBedfordP, 2002. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66: 533–541.)| false
• Search Google Scholar
• Export Citation

Monath TP, 2001. Yellow fever: an update. Lancet Infect Dis 1: 11–20.

MonathTP, 2001. Yellow fever: an update. Lancet Infect Dis 1: 11–20.)| false
• Search Google Scholar
• Export Citation

Niedrig M, Kursteiner O, Herzog C, Sonnenberg K, 2008. Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus. Clin Vaccine Immunol 15: 177–181.

NiedrigMKursteinerOHerzogCSonnenbergK, 2008. Evaluation of an indirect immunofluorescence assay for detection of immunoglobulin M (IgM) and IgG antibodies against yellow fever virus. Clin Vaccine Immunol 15: 177–181.)| false
• Search Google Scholar
• Export Citation

Wisseman CL Jr, Sweet BH, 1962. Immunological studies with group B arthropod-borne viruses. III. Response of human subjects to revaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg 11: 570–575.

WissemanCLJrSweetBH, 1962. Immunological studies with group B arthropod-borne viruses. III. Response of human subjects to revaccination with 17D strain yellow fever vaccine. Am J Trop Med Hyg 11: 570–575.)| false
• Search Google Scholar
• Export Citation

Omilabu SA, Adejumo JO, Olaleye OD, Fagbami AH, Baba SS, 1990. Yellow fever haemagglutination-inhibiting, neutralising and IgM antibodies in vaccinated and unvaccinated residents of Ibadan, Nigeria. Comp Immunol Microbiol Infect Dis 13: 95–100.

OmilabuSAAdejumoJOOlaleyeODFagbamiAHBabaSS, 1990. Yellow fever haemagglutination-inhibiting, neutralising and IgM antibodies in vaccinated and unvaccinated residents of Ibadan, Nigeria. Comp Immunol Microbiol Infect Dis 13: 95–100.)| false
• Search Google Scholar
• Export Citation

Munoz-Jordan JL, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, Lipkin WI, García-Sastre A, 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 79: 8004–8013.

Munoz-JordanJLLaurent-RolleMAshourJMartinez-SobridoLAshokMLipkinWIGarcía-SastreA, 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 79: 8004–8013.)| false
• Search Google Scholar
• Export Citation

Bonnevie-Nielsen V, Heron I, Monath TP, Calisher CH, 1995. Lymphocytic 2′,5′-oligoadenylate synthetase activity increases prior to the appearance of NTAbs and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diagn Lab Immunol 2: 302–306.

Bonnevie-NielsenVHeronIMonathTPCalisherCH, 1995. Lymphocytic 2′,5′-oligoadenylate synthetase activity increases prior to the appearance of NTAbs and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diagn Lab Immunol 2: 302–306.)| false
• Search Google Scholar
• Export Citation

Bruyand M, Receveur MC, Pistone T, Verdiere CH, Thiebaut R, Malvy D, 2008. Yellow fever vaccination in non-immunocompetent patients [in French]. Med Mal Infect 38: 524–532.

BruyandMReceveurMCPistoneTVerdiereCHThiebautRMalvyD, 2008. Yellow fever vaccination in non-immunocompetent patients [in French]. Med Mal Infect 38: 524–532.)| false
• Search Google Scholar
• Export Citation

Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T, 2011. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine 29: 4544–4555.

ThomasRELorenzettiDLSpraginsWJacksonDWilliamsonT, 2011. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine 29: 4544–4555.)| false
• Search Google Scholar
• Export Citation

Duchet Niedziolka P, Launay O, Salmon Ceron D, Consigny PH, Ancelle T, Van der Vliet D, Lortholary O, Hanslik T; pour fe groupe GEVACCIM, 2008. Antiviral immunization of immunocompromised adults, literature review [in French]. Rev Med Interne 29: 554–567.

Duchet NiedziolkaPLaunayOSalmon CeronDConsignyPHAncelleTVan der VlietDLortholaryOHanslikT; pour fe groupe GEVACCIM, 2008. Antiviral immunization of immunocompromised adults, literature review [in French]. Rev Med Interne 29: 554–567.)| false
• Search Google Scholar
• Export Citation

Dick GW, Smithburn KC, 1949. Immunity to yellow fever 6 year(s) after vaccination. Am J Trop Med Hyg 29: 57–61.

DickGWSmithburnKC, 1949. Immunity to yellow fever 6 year(s) after vaccination. Am J Trop Med Hyg 29: 57–61.)| false
• Search Google Scholar
• Export Citation

Anderson CR, Gast-Galvis A, 1947. Immunity to yellow fever five year(s) after vaccination. Am J Hyg 45: 302–304.

AndersonCRGast-GalvisA, 1947. Immunity to yellow fever five year(s) after vaccination. Am J Hyg 45: 302–304.)| false
• Search Google Scholar
• Export Citation

Fox JP, Fonseca Da Cunha J, Kossobudzki SL, 1948. Additional observations on the duration of humoral immunity following vaccination with the 17D strain of yellow fever virus. Am J Hyg 47: 64–70.

FoxJPFonseca Da CunhaJKossobudzkiSL, 1948. Additional observations on the duration of humoral immunity following vaccination with the 17D strain of yellow fever virus. Am J Hyg 47: 64–70.)| false
• Search Google Scholar
• Export Citation

Veras MA, Flannery B, de Moraes JC, da Silva Teixeira AM, Luna EJ; Vaccine Coverage Survey 2007 Group, 2010. Yellow fever vaccination coverage among children in Brazilian capitals. Vaccine 28: 6478–6482.

VerasMAFlanneryBde MoraesJCda Silva TeixeiraAMLunaEJ; Vaccine Coverage Survey 2007 Group, 2010. Yellow fever vaccination coverage among children in Brazilian capitals. Vaccine 28: 6478–6482.)| false
• Search Google Scholar
• Export Citation

Lopes O de S, Guimaraes SS, de Carvalho R, 1988. Studies on yellow fever vaccine. III. Dose response in volunteers. J Biol Stand 16: 77–82.

LopesO de SGuimaraesSSde CarvalhoR, 1988. Studies on yellow fever vaccine. III. Dose response in volunteers. J Biol Stand 16: 77–82.)| false
• Search Google Scholar
• Export Citation

Stefano I, Sato HK, Pannuti CS, Omoto TM, Mann G, Freire MS, Yamamura AM, Vasconcelos PF, Oselka GW, Weckx LW, Salgado MF, Noale LF, Souza VA, 1999. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. Vaccine 17: 1042–1046.

StefanoISatoHKPannutiCSOmotoTMMannGFreireMSYamamuraAMVasconcelosPFOselkaGWWeckxLWSalgadoMFNoaleLFSouzaVA, 1999. Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. Vaccine 17: 1042–1046.)| false
• Search Google Scholar
• Export Citation

Receveur MC, Thiebaut R, Vedy S, Malvy D, Mercie P, Bras ML, 2000. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin Infect Dis 31: 7–8.

ReceveurMCThiebautRVedySMalvyDMerciePBrasML, 2000. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases. Clin Infect Dis 31: 7–8.)| false
• Search Google Scholar
• Export Citation

Tattevin P, Depatureaux AG, Chapplain JM, Dupont M, Souala F, Arvieux C, Poveda JD, Michelat C, 2004. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS 18: 825–827.

TattevinPDepatureauxAGChapplainJMDupontMSoualaFArvieuxCPovedaJDMichelatC, 2004. Yellow fever vaccine is safe and effective in HIV-infected patients. AIDS 18: 825–827.)| false
• Search Google Scholar
• Export Citation

Pistone T, Verdiere CH, Receveur MC, Ezzedine K, Lafon ME, Malvy D, 2010. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients. Curr HIV Res 8: 461–466.

PistoneTVerdiereCHReceveurMCEzzedineKLafonMEMalvyD, 2010. Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients. Curr HIV Res 8: 461–466.)| false
• Search Google Scholar
• Export Citation

Sidibe M, Yactayo S, Kalle A, Sall AA, Sow S, Ndoutabe M, Perea W, Avokey F, Lewies RF, Veit O, 2012. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali. Trans R Soc Trop Med Hyg 106: 437–444.

SidibeMYactayoSKalleASallAASowSNdoutabeMPereaWAvokeyFLewiesRFVeitO, 2012. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali. Trans R Soc Trop Med Hyg 106: 437–444.)| false
• Search Google Scholar
• Export Citation

Sibailly TS, Wiktor SZ, Tsai TF, Cropp BC, Ekpini ER, Adjorlolo-Johnson G, Gnaore G, De Cock KM, Greenberg AE, 1997. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 16: 1177–1179.

SibaillyTSWiktorSZTsaiTFCroppBCEkpiniERAdjorlolo-JohnsonGGnaoreGDe CockKMGreenbergAE, 1997. Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J 16: 1177–1179.)| false
• Search Google Scholar
• Export Citation

Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P, Bae HE, Litzba N, Staub T, Hatz C, Furrer H; Swiss HIV Cohort Study, 2009. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 48: 659–666.

VeitONiedrigMChapuis-TaillardCCavassiniMMossdorfESchmidPBaeHELitzbaNStaubTHatzCFurrerH; Swiss HIV Cohort Study, 2009. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 48: 659–666.)| false
• Search Google Scholar
• Export Citation

Pacanowski J, Lacombe K, Campa P, Dabrowska M, Poveda JD, Meynard JL, Poirot JL, Fonquernie L, Girard PM, 2012. Plasma HIV-RNA is the key determinant of long-term antibody persistence after yellow fever immunization in a cohort of 364 HIV-infected patients. J Acquir Immune Defic Syndr 59: 360–367.

PacanowskiJLacombeKCampaPDabrowskaMPovedaJDMeynardJLPoirotJLFonquernieLGirardPM, 2012. Plasma HIV-RNA is the key determinant of long-term antibody persistence after yellow fever immunization in a cohort of 364 HIV-infected patients. J Acquir Immune Defic Syndr 59: 360–367.)| false
• Search Google Scholar
• Export Citation

Nasidi A, Monath TP, Vandenberg J, Tomori O, Calisher CH, Hurtgen X, Munube GR, Sorungbe AO, Okafor GC, Wali S, 1993. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg 87: 337–339.

NasidiAMonathTPVandenbergJTomoriOCalisherCHHurtgenXMunubeGRSorungbeAOOkaforGCWaliS, 1993. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg 87: 337–339.)| false
• Search Google Scholar
• Export Citation

Brown RE, Katz M, 1966. Failure of antibody production to yellow fever vaccine in children with kwashiorkor. Trop Geogr Med 18: 125–128.

BrownREKatzM, 1966. Failure of antibody production to yellow fever vaccine in children with kwashiorkor. Trop Geogr Med 18: 125–128.)| false
• Search Google Scholar
• Export Citation

Anonymous, 1967. Effects of malnutrition on smallpox and yellow fever vaccination. Nutr Rev 25: 108–110.

Anonymous, 1967. Effects of malnutrition on smallpox and yellow fever vaccination. Nutr Rev 25: 108–110.)| false
• Search Google Scholar
• Export Citation

Monath TP, Gershman M, Barret AD, 2012. Yellow fever. Plotkin S, Orenstein W, eds. Vaccines. Sixth Edition. Philadelphia, PA: W. B. Saunders, 870–968.

MonathTPGershmanMBarretAD, 2012. Yellow fever. PlotkinSOrensteinW, eds. Vaccines. Sixth Edition. Philadelphia, PA: W. B. Saunders, 870–968.)| false
• Search Google Scholar
• Export Citation

Groot H, Kerr JA, Sanmartin C, Vidales H, 1959. Antibodies to yellow fever and other arthropod-borne viruses in human residents of San Vicente de Chucuri, Santander, Colombia. Am J Trop Med Hyg 8: 175–189.

GrootHKerrJASanmartinCVidalesH, 1959. Antibodies to yellow fever and other arthropod-borne viruses in human residents of San Vicente de Chucuri, Santander, Colombia. Am J Trop Med Hyg 8: 175–189.)| false
• Search Google Scholar
• Export Citation

Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, Moser JM, Mehta RS, Drake DR III, Castro E, Akondy R, Rinfret A, Yassine-Diab B, Said EA, Chouikh Y, Cameron MJ, Clum R, Kelvin D, Somogyi R, Greller LD, Balderas RS, Wilkinson P, Pantaleo G, Tartaglia J, Hadad EK, Sékaly RP, 2008. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119–3131.

GaucherDTherrienRKettafNAngermannBRBoucherGFilali-MouhimAMoserJMMehtaRSDrakeDRIIICastroEAkondyRRinfretAYassine-DiabBSaidEAChouikhYCameronMJClumRKelvinDSomogyiRGrellerLDBalderasRSWilkinsonPPantaleoGTartagliaJHadadEKSékalyRP, 2008. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119–3131.)| false
• Search Google Scholar
• Export Citation

Anonymous, 2010. Yellow fever fact sheet. Wkly Epidemiol Rec 85: 33–36.

Anonymous, 2010. Yellow fever fact sheet. Wkly Epidemiol Rec 85: 33–36.)| false
• Search Google Scholar
• Export Citation

Fox JP, Elveback L, Scott W, Gatewood L, Ackerman E, 1995. Herd immunity: basic concept and relevance to public health immunization practices. Am J Epidemiol 141: 187–197.

FoxJPElvebackLScottWGatewoodLAckermanE, 1995. Herd immunity: basic concept and relevance to public health immunization practices. Am J Epidemiol 141: 187–197.)| false
• Search Google Scholar
• Export Citation

Goujon CT, Feuillie V, Coulaud P, Dupont B, Sansonetti P, 1995. Good tolerance and efficacy of yellow fever vaccine among carriers of human immunodeficiency virus. J Travel Med 2.

GoujonCTFeuillieVCoulaudPDupontBSansonettiP, 1995. Good tolerance and efficacy of yellow fever vaccine among carriers of human immunodeficiency virus. J Travel Med 2.)| false
• Search Google Scholar
• Export Citation

Pacanowski JC, Dabrowska M, Lacombe K, 2008. Antibody response and safety of yellow fever vaccination in HIV infected patients. Proceedings of the 48th Annual International Conference on Antimicrobial Agents and Chemotherapy, October 25–28, 2008, Washington, DC.

PacanowskiJCDabrowskaMLacombeK, 2008. Antibody response and safety of yellow fever vaccination in HIV infected patients. Proceedings of the 48th Annual International Conference on Antimicrobial Agents and Chemotherapy, October 25–28, 2008, Washington, DC.)| false
• Search Google Scholar
• Export Citation

Anonymous, 1996. Expanded programme on immunization (EPI). Inclusion of yellow fever vaccine in the EPI. Wkly Epidemiol Rec 71: 181–185.

Anonymous, 1996. Expanded programme on immunization (EPI). Inclusion of yellow fever vaccine in the EPI. Wkly Epidemiol Rec 71: 181–185.)| false
• Search Google Scholar
• Export Citation

Monath TP, 2006. Yellow fever as an endemic/epidemic disease and priorities for vaccination. Bull Soc Pathol Exot 99: 341–347.

MonathTP, 2006. Yellow fever as an endemic/epidemic disease and priorities for vaccination. Bull Soc Pathol Exot 99: 341–347.)| false
• Search Google Scholar
• Export Citation

Hanson H, 1929. Observations on the age and sex incidence of deaths and recoveries in the yellow fever epidemic in the department of Lambayeque, Peru, in 1921. Am J Trop Med 9: 233–239.

HansonH, 1929. Observations on the age and sex incidence of deaths and recoveries in the yellow fever epidemic in the department of Lambayeque, Peru, in 1921. Am J Trop Med 9: 233–239.)| false
• Search Google Scholar
• Export Citation

Monath TP, Craven RB, Adjukiewicz A, Germain M, Francy DB, Ferrara L, Samba EM, N'Jie H, Cham K, Fitzgerald SA, Crippen PH, Simpson DI, Bowen ET, Fabiyi A, Salaun JJ, 1980. Yellow fever in the Gambia, 1978–1979: epidemiologic aspects with observations on the occurrence of Orungo virus infections. Am J Trop Med Hyg 29: 912–928.

MonathTPCravenRBAdjukiewiczAGermainMFrancyDBFerraraLSambaEMN'JieHChamKFitzgeraldSACrippenPHSimpsonDIBowenETFabiyiASalaunJJ, 1980. Yellow fever in the Gambia, 1978–1979: epidemiologic aspects with observations on the occurrence of Orungo virus infections. Am J Trop Med Hyg 29: 912–928.)| false
• Search Google Scholar
• Export Citation

Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, Lindstrom S, Louie JK, Christ CM, Bohm MR, Fonseca VP, Ritger KA, Kuhles DJ, Eggers P, Bruce H, Davidson HA, Lutterloh E, Harris ML, Burke C, Cocoros N, Finelli L, MacFarlane KF, Shu B, Olsen SJ; Novel Influenza A (H1N1) Pregancy Working Group, 2009. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 374: 451–458.

JamiesonDJHoneinMARasmussenSAWilliamsJLSwerdlowDLBiggerstaffMSLindstromSLouieJKChristCMBohmMRFonsecaVPRitgerKAKuhlesDJEggersPBruceHDavidsonHALutterlohEHarrisMLBurkeCCocorosNFinelliLMacFarlaneKFShuBOlsenSJ; Novel Influenza A (H1N1) Pregancy Working Group, 2009. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 374: 451–458.)| false
• Search Google Scholar
• Export Citation

Ingardia CJ, Kelley L, Steinfeld JD, Wax JR, 1999. Hepatitis B vaccination in pregnancy: factors influencing efficacy. Obstet Gynecol 93: 983–986.

IngardiaCJKelleyLSteinfeldJDWaxJR, 1999. Hepatitis B vaccination in pregnancy: factors influencing efficacy. Obstet Gynecol 93: 983–986.)| false
• Search Google Scholar
• Export Citation

Nishioka S de A, Nunes-Araujo FR, Pires WP, Silva FA, Costa HL, 1998. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop Med Int Health 3: 29–33.

NishiokaS de ANunes-AraujoFRPiresWPSilvaFACostaHL, 1998. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop Med Int Health 3: 29–33.)| false
• Search Google Scholar
• Export Citation

Cavalcanti DP, Salomao MA, Lopez-Camelo J, Pessoto MA; Campinas Group of Yellow Fever Immunization during Pregnancy, 2007. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health 12: 833–837.

CavalcantiDPSalomaoMALopez-CameloJPessotoMA; Campinas Group of Yellow Fever Immunization during Pregnancy, 2007. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health 12: 833–837.)| false
• Search Google Scholar
• Export Citation

Elliot M, 1944. Yellow fever in the recently inoculated. Trans R Soc Trop Med Hyg 38: 231–236.

ElliotM, 1944. Yellow fever in the recently inoculated. Trans R Soc Trop Med Hyg 38: 231–236.)| false
• Search Google Scholar
• Export Citation

Ross RW, Haddow AJ, Raper AB, Trowell HC, 1953. A fatal case of yellow fever in a European in Uganda. East Afr Med J 30: 1–11.

RossRWHaddowAJRaperABTrowellHC, 1953. A fatal case of yellow fever in a European in Uganda. East Afr Med J 30: 1–11.)| false
• Search Google Scholar
• Export Citation

Nolla-Salas J, Saballs-Radresa J, Bada JL, 1989. Imported yellow fever in vaccinated tourist. Lancet 334: 1275.

Nolla-SalasJSaballs-RadresaJBadaJL, 1989. Imported yellow fever in vaccinated tourist. Lancet 334: 1275.)| false
• Search Google Scholar
• Export Citation

Tuboi SH, Costa ZG, da Costa Vasconcelos PF, Hatch D, 2007. Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998–2002. Trans R Soc Trop Med Hyg 101: 169–175.

TuboiSHCostaZGda Costa VasconcelosPFHatchD, 2007. Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998–2002. Trans R Soc Trop Med Hyg 101: 169–175.)| false
• Search Google Scholar
• Export Citation

McFarland JM, Baddour LM, Nelson JE, Elkins SK, Craven RB, Cropp BC, Chang GJ, Grindstaff AD, Craig AS, Smith RJ, 1997. Imported yellow fever in a United States citizen. Clin Infect Dis 25: 1143–1147.

McFarlandJMBaddourLMNelsonJEElkinsSKCravenRBCroppBCChangGJGrindstaffADCraigASSmithRJ, 1997. Imported yellow fever in a United States citizen. Clin Infect Dis 25: 1143–1147.)| false
• Search Google Scholar
• Export Citation

Barros ML, Boecken G, 1996. Jungle yellow fever in the central Amazon. Lancet 348: 969–970.

BarrosMLBoeckenG, 1996. Jungle yellow fever in the central Amazon. Lancet 348: 969–970.)| false
• Search Google Scholar
• Export Citation

Bae HG, Drosten C, Emmerich P, Colebunders R, Hantson P, Pest S, Parent M, Schmitz H, Warnat MA, Niedrig M, 2005. Analysis of two imported cases of yellow fever infection from Ivory Coast and The Gambia to Germany and Belgium. J Clin Virol 33: 274–280.